Noxopharm logo

Noxopharm(ASX) NOX

Market CapA$18.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-63%
5 Year-90%
1 Year-34%
1 Month-13%
A$0.06
-1.61%
-0.00Today
Noxopharm last closing stock price
MetricPriceDate
Last closeAUD 0.062026-10-08
Noxopharm stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.39%AUD 0.062026-09-30
1 month-12.86%AUD 0.072026-09-08
3 month-32.97%AUD 0.092026-07-10
Year to date-34.41%AUD 0.092025-12-31
1 year-34.41%AUD 0.092025-10-08
3 year-44.55%AUD 0.112023-10-09
5 year-89.66%AUD 0.592021-10-08
Since inception-62.66%AUD 0.162016-08-09

Noxopharm Financials at a Glance

Market Cap

A$18.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$2.82M

Net Income (TTM)

-A$9.34M

EPS (TTM)

-A$0.02

P/E Ratio

-4.07

Dividend

A$0.00

Beta (Volatility)

-0.04 (Low)

Price

A$0.06

Volume

0

Open

A$0.06

Previous Close

A$0.06

Daily Range

A$0.06 - A$0.06

52-Week Range

A$0.05 - A$0.11

Estimated Earnings Date

Feb 23, 2026

NOX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Noxopharm

Noxopharm Limited is an Australian biotechnology company dedicated to developing innovative treatments for solid tumor cancers and septic shock. The company focuses on its lead asset, Veyonda, which enhances the effectiveness of chemotherapy and radiotherapy for late-stage cancers.

Products and Services
  • Veyonda: An adjuvant therapy for late-stage cancers
  • DARRT program: Targeting metastatic castration-resistant prostate cancer
  • NOXCOVID Program: Investigating NOX66 for COVID-19 treatment
Growth Outlook
  • Ongoing clinical trials for Veyonda show promising results
  • Expansion into advanced prostate cancer therapies with LuPIN program
  • Collaboration with leading research institutions enhances development capabilities
Financial Highlights
  • Recent quarterly revenue of AUD 0 indicates ongoing development phase
  • Trailing twelve months (TTM) net income loss of AUD 2.6 million
  • Cash and cash equivalents of AUD 293,573 as of June 30, 2026
Noxopharm Limited operates in a highly competitive biotechnology sector, focusing on innovative solutions for serious health conditions. The company's primary asset, Veyonda, is positioned to augment existing cancer therapies, potentially improving patient outcomes. The DARRT and LuPIN programs further diversify the pipeline, targeting specific cancer types with tailored approaches. Recent collaborations with esteemed research institutions bolster the company's research capabilities, enhancing its potential for breakthroughs in treatment. Financially, Noxopharm is in a development phase, with no revenue reported in the latest quarter, reflecting the investment in research and development. The trailing twelve months show a net income loss, indicative of the costs associated with advancing clinical trials and operational expenses. The current cash position suggests a need for ongoing funding to support its ambitious development agenda. Overall, Noxopharm Limited presents a compelling opportunity for investors interested in the biotechnology sector, particularly in innovative cancer therapies.
AI Generated • Sep 23, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Olivier Laczka, PhD

Website

www.noxopharm.com

Headquarters

Glenhaven, NSW 2156, AU

NOX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

186.62%

Return on Capital

-523.73%

Return on Assets

-242.56%

Earnings Yield

-24.57%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$18.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

307.24M

Volume

0

Avg. Volume

75.69K

Financials (TTM)

Gross Profit

-A$1.45M

Operating Income

-A$14.50M

EBITDA

-A$10.23M

Operating Cash Flow

-A$8.54M

Capital Expenditure

A$1.86K

Free Cash Flow

-A$8.54M

Cash & ST Invst.

A$293.57K

Total Debt

A$4.57M

Noxopharm Performance Analysis

Noxopharm annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
20262026-06-30AUD 0N/A
Noxopharm sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-2.7%
Q42025-06-3044.0%
Q22025-12-31-100.0%
Q42026-06-30N/A
Noxopharm annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.05-19.7%
20242024-06-30AUD -0.01-76.3%
20252025-06-30AUD -0.0236.9%
20262026-06-30AUD -0.02-10.2%
Noxopharm sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-13.5%
Q42025-06-30-197.6%
Q22025-12-3149.6%
Q42026-06-30-42.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$864.00

+99.7%

Gross Margin

0.00%

N/A

Market Cap

A$18.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$2.34M

N/A

Employees

8

N/A

Net Income

-A$2.61M

-142.0%

EBITDA

-A$1.83M

+22.0%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$293.57K

-87.3%

Total Debt

A$4.57M

N/A

Accounts Receivable

A$1.51M

-37.2%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$4.57M

N/A

Return on Assets

-2.43%

N/A

Return on Invested Capital

1.34%

N/A

Free Cash Flow

A$0.00

+100.0%

Operating Cash Flow

-A$1.86K

+99.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IDT.AXIDT Australia Limited
A$0.04+2.70%
OSL.AXOncoSil Medical Ltd
A$0.70-1.41%
IMC.AXImmuron Limited
A$0.05+0.00%
RHY.AXRhythm Biosciences Limited
A$0.08+4.17%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.19-9.79%
WFFWf
$7.31+256.54%
VEEAVeea
$5.72+47.80%
SPCXSpace Exploration Technologies
$161.67+0.68%

Questions About NOX

What is the current price of Noxopharm?

Noxopharm is trading at A$0.06 per share.

What is the 52-week range for Noxopharm?

Over the past 52 weeks, Noxopharm has traded between A$0.05 and A$0.11.

How much debt does Noxopharm have?

As of the most recent reporting period, Noxopharm reported total debt of A$4.57M.

How much cash does Noxopharm have on hand?

Noxopharm reported A$293.57K in cash and cash equivalents in its most recent financial results.

What is Noxopharm’s dividend yield?

Noxopharm does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services